Coronavirus Update: Vaccine Companies To Update Lawmakers As Crisis Deepens In US
Plus: Novartis Q2 Affected
Executives from Moderna, Pfizer and AstraZeneca and others will give politicians in Washington DC an update on the progress of their vaccine - but will resist pressure to make promises of a breakthrough in 2020.
You may also be interested in...
Glenmark's Phase III trial of the antiviral points to efficacy in mild-to-moderate COVID-19, but many physicians in India remain skeptical.
While data from small trials are difficult to compare, it appears that T-cell responses to BNT162b1 may be stronger than those reported so far for Moderna’s competing mRNA-based vaccine.
More news from across the sector, including Novartis's non-profit pledge on medicines and Zydus Cadila commencing Phase I vaccine trial.